Literature DB >> 29630692

Associations Between Brain Structure and Connectivity in Infants and Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy.

Claudia Lugo-Candelas1,2, Jiook Cha1,2, Susie Hong1,2, Vanessa Bastidas1,2, Myrna Weissman1,2,3, William P Fifer1,2,3, Michael Myers1,2,3, Ardesheer Talati1,2,3, Ravi Bansal4,5, Bradley S Peterson4,5, Catherine Monk1,2,3, Jay A Gingrich1,2,3, Jonathan Posner1,2,3.   

Abstract

Importance: Selective serotonin reuptake inhibitor (SSRI) use among pregnant women is increasing, yet the association between prenatal SSRI exposure and fetal neurodevelopment is poorly understood. Animal studies show that perinatal SSRI exposure alters limbic circuitry and produces anxiety and depressive-like behaviors after adolescence, but literature on prenatal SSRI exposure in humans is limited and mixed. Objective: To examine associations between prenatal SSRI exposure and brain development using structural and diffusion magnetic resonance imaging (MRI). Design, Setting, and Participants: A cohort study conducted at Columbia University Medical Center and New York State Psychiatric Institute included 98 infants: 16 with in utero SSRI exposure, 21 with in utero untreated maternal depression exposure, and 61 healthy controls. Data were collected between January 6, 2011, and October 25, 2016. Exposures: Selective serotonin reuptake inhibitors and untreated maternal depression. Main Outcomes and Measures: Gray matter volume estimates using structural MRI with voxel-based morphometry and white matter structural connectivity (connectome) using diffusion MRI with probabilistic tractography.
Results: The sample included 98 mother (31 [32%] white, 26 [27%] Hispanic/Latina, 26 [27%] black/African American, 15 [15%] other) and infant (46 [47%] boys, 52 [53%] girls) dyads. Mean (SD) age of the infants at the time of the scan was 3.43 (1.50) weeks. Voxel-based morphometry showed significant gray matter volume expansion in the right amygdala (Cohen d = 0.65; 95% CI, 0.06-1.23) and right insula (Cohen d = 0.86; 95% CI, 0.26-1.14) in SSRI-exposed infants compared with both healthy controls and infants exposed to untreated maternal depression (P < .05; whole-brain correction). In connectome-level analysis of white matter structural connectivity, the SSRI group showed a significant increase in connectivity between the right amygdala and the right insula with a large effect size (Cohen d = 0.99; 95% CI, 0.40-1.57) compared with healthy controls and untreated depression (P < .05; whole connectome correction). Conclusions and Relevance: Our findings suggest that prenatal SSRI exposure has an association with fetal brain development, particularly in brain regions critical to emotional processing. The study highlights the need for further research on the potential long-term behavioral and psychological outcomes of these neurodevelopmental changes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29630692      PMCID: PMC6137537          DOI: 10.1001/jamapediatrics.2017.5227

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  46 in total

1.  Feeling anxious: anticipatory amygdalo-insular response predicts the feeling of anxious anticipation.

Authors:  Joshua M Carlson; Tsafrir Greenberg; Denis Rubin; Lilianne R Mujica-Parodi
Journal:  Soc Cogn Affect Neurosci       Date:  2010-03-05       Impact factor: 3.436

2.  Newborn Brain Function Is Affected by Fetal Exposure to Maternal Serotonin Reuptake Inhibitors.

Authors:  Mari Videman; Anton Tokariev; Heini Saikkonen; Susanna Stjerna; Hannu Heiskala; Outi Mantere; Sampsa Vanhatalo
Journal:  Cereb Cortex       Date:  2017-06-01       Impact factor: 5.357

3.  Antenatal exposure to antidepressants is associated with altered brain development in very preterm-born neonates.

Authors:  Samantha K Podrebarac; Emma G Duerden; Vann Chau; Ruth E Grunau; Anne Synnes; Tim F Oberlander; Steven P Miller
Journal:  Neuroscience       Date:  2016-11-25       Impact factor: 3.590

4.  Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy.

Authors:  Tim F Oberlander; Pratibha Reebye; Shaila Misri; Michael Papsdorf; John Kim; Ruth E Grunau
Journal:  Arch Pediatr Adolesc Med       Date:  2007-01

5.  Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder.

Authors:  Amit Etkin; Katherine E Prater; Alan F Schatzberg; Vinod Menon; Michael D Greicius
Journal:  Arch Gen Psychiatry       Date:  2009-12

6.  Uncertainty during anticipation modulates neural responses to aversion in human insula and amygdala.

Authors:  I Sarinopoulos; D W Grupe; K L Mackiewicz; J D Herrington; M Lor; E E Steege; J B Nitschke
Journal:  Cereb Cortex       Date:  2009-08-13       Impact factor: 5.357

7.  Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development.

Authors:  Yanling Xu; Youssef Sari; Feng C Zhou
Journal:  Brain Res Dev Brain Res       Date:  2004-06-21

Review 8.  Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature.

Authors:  Veronika Kiryanova; Brendan B McAllister; Richard H Dyck
Journal:  Dev Neurosci       Date:  2013       Impact factor: 2.984

9.  Between session reproducibility and between subject variability of diffusion MR and tractography measures.

Authors:  E Heiervang; T E J Behrens; C E Mackay; M D Robson; H Johansen-Berg
Journal:  Neuroimage       Date:  2006-09-26       Impact factor: 6.556

10.  Alterations in amygdala-prefrontal circuits in infants exposed to prenatal maternal depression.

Authors:  J Posner; J Cha; A K Roy; B S Peterson; R Bansal; H C Gustafsson; E Raffanello; J Gingrich; C Monk
Journal:  Transl Psychiatry       Date:  2016-11-01       Impact factor: 6.222

View more
  33 in total

1.  Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy.

Authors:  Madhurima Saha; Skylar A Rizzo; Manashwi Ramanathan; Rylie M Hightower; Katherine E Santostefano; Naohiro Terada; Richard S Finkel; Jonathan S Berg; Nizar Chahin; Christina A Pacak; Richard E Wagner; Matthew S Alexander; Isabelle Draper; Peter B Kang
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

2.  Neonatal infant EEG bursts are altered by prenatal maternal depression and serotonin selective reuptake inhibitor use.

Authors:  P G Grieve; W P Fifer; N P Cousy; C E Monk; R I Stark; J A Gingrich; M M Myers
Journal:  Clin Neurophysiol       Date:  2019-09-03       Impact factor: 3.708

3.  Maternal use of selective serotonin reuptake inhibitors (SSRI) during pregnancy-neonatal outcomes in correlation with placental histopathology.

Authors:  Michal Levy; Michal Kovo; Hadas Miremberg; Noa Anchel; Hadas Ganer Herman; Jacob Bar; Letizia Schreiber; Eran Weiner
Journal:  J Perinatol       Date:  2020-01-27       Impact factor: 2.521

4.  Association of Maternal Psychological Distress With In Utero Brain Development in Fetuses With Congenital Heart Disease.

Authors:  Yao Wu; Kushal Kapse; Marni Jacobs; Nickie Niforatos-Andescavage; Mary T Donofrio; Anita Krishnan; Gilbert Vezina; David Wessel; Adré du Plessis; Catherine Limperopoulos
Journal:  JAMA Pediatr       Date:  2020-03-02       Impact factor: 16.193

Review 5.  Prenatal Developmental Origins of Future Psychopathology: Mechanisms and Pathways.

Authors:  Catherine Monk; Claudia Lugo-Candelas; Caroline Trumpff
Journal:  Annu Rev Clin Psychol       Date:  2019-02-22       Impact factor: 18.561

6.  Examining the relationship between perinatal depression and neurodevelopment in infants and children through structural and functional neuroimaging research.

Authors:  Christy Duan; Megan M Hare; Morganne Staring; Kristina M Deligiannidis
Journal:  Int Rev Psychiatry       Date:  2019-01-31

7.  A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders.

Authors:  Bradley S Peterson; Amy E West; John R Weisz; Wendy J Mack; Michele D Kipke; Robert L Findling; Brian S Mittman; Ravi Bansal; Steven Piantadosi; Glenn Takata; Corinna Koebnick; Ceth Ashen; Christopher Snowdy; Marie Poulsen; Bhavana Kumar Arora; Courtney M Allem; Marisa Perez; Stephanie N Marcy; Bradley O Hudson; Stephanie H Chan; Robin Weersing
Journal:  BMC Psychiatry       Date:  2021-06-30       Impact factor: 3.630

8.  Structural neural markers of response to cognitive behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  David Pagliaccio; Jiook Cha; Xiaofu He; Marilyn Cyr; Paula Yanes-Lukin; Pablo Goldberg; Martine Fontaine; Moira A Rynn; Rachel Marsh
Journal:  J Child Psychol Psychiatry       Date:  2019-12-31       Impact factor: 8.982

Review 9.  The Roles of Serotonin in Neuropsychiatric Disorders.

Authors:  Mahsa Pourhamzeh; Fahimeh Ghasemi Moravej; Mehrnoosh Arabi; Elahe Shahriari; Soraya Mehrabi; Richard Ward; Reza Ahadi; Mohammad Taghi Joghataei
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

10.  Brexanolone for the treatment of patients with postpartum depression.

Authors:  K E Morrison; A B Cole; S M Thompson; T L Bale
Journal:  Drugs Today (Barc)       Date:  2019-09       Impact factor: 2.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.